



ten23 health® launches GMP certified quality control & testing services at its state-of-the-art Basel and Visp facilities in Switzerland

ten23 health® proudly launches its GMP certified Quality Control (QC) & Testing services at its state-of-the-art Basel (BASE®) and Visp (VIVA2®) laboratories in Switzerland, celebrated with a grand opening in Basel featuring local dignitaries.

Basel, Switzerland, April 28, 2025 – ten23 health®, the human-centric und sustainable contract development and manufacturing organization, announces the launch of its quality control (QC) & testing services at both its Basel (BASE®) and Visp (VIVA2®) facilities, following the receipt of all related GMP licenses. The services were officially launched with an inaugural event, attended by **Christof Klöpper**, CEO Basel Area Swiss, and **Samuel Hess**, Economic Development Basel-Stadt as well as ten23's **Ivana Heckel** (Head of QC), **Susanne Jörg** (COO), **Nadine Mendl** (Lead, QC Basel) & **Hanns-Christian Mahler** (CEO).

The new QC services complement ten23's existing capabilities. These include development services at the Basel (BASE®) facility for formulation development, analytical method development, and specialized testing, such as Particulate and Container Closure Integrity (CCI) testing. Additionally, they seamlessly align with ten23's GMP manufacturing services for clinical and commercial sterile products at their VIVA1® and VIVA2® facilities in Visp, ensuring comprehensive service offerings for sterile products, and end-to-end customer support.

The new QC laboratories in Basel and Visp became operational in 2024. Now, in 2025, the labs have obtained GMP establishment licenses from Swissmedic, certifying the organization's unwavering commitment to upholding the highest standards of quality and compliance. ten23 has already started QC operations, servicing its first customer projects for QC release and stability testing services.

"Having obtained the GMP licenses for our QC services laboratories in both Basel and Visp represents a pivotal moment for ten23 health and underscores our dedication to Swiss excellence in providing integrated services for pharmaceutical development, manufacturing and testing," commented Dr. Susanne Jörg, Chief Customer Delivery Officer (COO) at ten23 health.

With the purpose-built QC services expansion, ten23 is now providing additional analytical services:

- QC laboratories in Basel (BASE®) provide analytical method validation and method transfer, QC release testing, and QC stability testing (at intended and accelerated storage conditions). The state-of-the-art technology and expertise includes tests for the determination of content, identity, purity by liquid chromatography and capillary electrophoresis, as well as compendial tests for parenteral preparations, such as visible particles, subvisible particles, color, clarity, density, pH, osmolality.





The services can be utilized for sterile products such as biologics, peptides, small molecules, bioconjugates and oligonucleotides.

- QC laboratories in Visp (VIVA2®) offer microbiological and a range of in-process-control testing. The microbiological methods include the full range of analytics from bioburden and endotoxin up to sterility testing, microbial challenge studies and low endotoxin recovery (LER) studies.

Customers can utilize ten23's QC testing services as stand-alone services or in conjunction with their development and/or manufacturing (fill & finish) services, benefiting from true integration at one service provider, from its two Swiss locations.

"We are pleased to announce this milestone, which further strengthens our position as an integrated, highly knowledgeable and trusted partner for sterile dosage forms in the CDMO landscape," stated Ivana Heckel, Head of QC at ten23 health.

About ten23 health

ten23 health®, located in Basel and Visp, Switzerland, is the human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups: we develop, manufacture, and test modern medicines. We support our clients in developing differentiated, stable, usable, and safe injectable treatment options for patients. ten23 health® combines the latest scientific findings with proven and tested world-class industry and regulatory expertise to forge new paths for supporting clients. We provide our innovative services in a fair and sustainable manner, respecting people's health and the future of our planet. ten23 health® is a B Corp member and solidly financed through the long-term commitment of 3i Group, an internationally reputable equity partner.

About the company's name

The numeric value for the number of molecules in a sample of one mol is called Avogadro constant and equals 6.022×10^{23} . Gram quantities of material contain the incredible number of 10^{23} atoms, which was an important discovery to understand the composition of matter: The world is built from small units, and not a homogeneous mass.

About 3i Group

3i is an investment company with two complementary businesses, Private Equity and Infrastructure, and invests in mid-market companies headquartered in Europe and North America. 3i's Private Equity team provides investment solutions for growing companies, backing entrepreneurs and management teams of companies with an EV typically between €100m – €500m. 3i backs international growth plans, providing access to its network and expertise to accelerate the growth of companies across the consumer, healthcare, industrial and private label, and services and software industries.

Media contacts:

ten23 health: Marija Petrovic marija.petrovic@ten23.health ; +41 78 694 87 33

3i Group: Kathryn van der Kroft, Kathryn.VanDerKroft@3i.com +44 20 7975 3021

